thanks to asculpeous and fisherking for opening my eyes to this huge health issue namely CKD.
I can now see how and why AXE answered the call to develop the right graphene based sensor for point of care. While there are other sensors, they are
1, more expensive 2. cannot detect biomarkers at low concentrations 3. take too long to detect 4. focus on detection of only single biomarkers, when detection of multiple markers is a must-have capability for reliable diagnosis 5. involves delicate handling of sensor equipment
the AXE bio chip is addressing every one of these issues in one go. I'm finally aware that a use case for a POC biosensing platform developed by AXE is ready and waiting. AXE has to somehow achieve and maintain high and quick sensitivity of the graphene surfaces. That is where it's at now. 'first demonstrator data' will establish a baseline validation of the biochip platform and the software analysis that will help with even less invasive patient interactions.
AXE Price at posting:
26.0¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)